HIMSS reports on 2016’s ‘growth technologies’

Michael Walter | | Health Exec | Healthcare Information Management Systems Society (HIMSS)

Healthcare Information and Management Systems Society (HIMSS) Analytics has published a report on some of the technologies shaping hospitals’ purchase plans in 2016.

Data analysis earned two different spots in the report’s list of “growth technologies” for 2016. Data Warehousing/Mining—Clinical is HIMSS’ No. 1 growth technology (188 hospitals planning to purchase, 102 planning to upgrade), and Data Warehousing/Mining—Financial came in at No. 13 (92 hospitals planning to purchase, 43 planning to upgrade).

Medical Necessity Checking Content (50 hospitals planning to purchase, 225 planning to upgrade) and Dictation with Speech Recognition (163 hospitals planning to purchase, 93 planning to upgrade) were also at the top of the list.

The report also noted that the increase of interest in certain technologies shows hospitals attempting to stay relevant within the evolving healthcare industry.

“The increased plans to replace billing and collection systems illustrates hospitals preparing for the shift to value-based payment,” the report stated.

More information about this report is available on the HIMSS Analytics website. 

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Related Content

Cloud image storage for radiology is a growing trend in healthcare
Indiana hospitals reduce nuisance alerts by 77% with medication decision support software
Trends and tips in healthcare cybersecurity 
Leveraging machine learning to rapidly create clinical AI algorithms
How medication reconciliation data consolidation in the EHR enables better patient care
How are the best in KLAS Health IT vendor rankings created?

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.